Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Other Non-Current Liabilities: 2020-2025

Historic Other Non-Current Liabilities for Xeris Biopharma Holdings (XERS) over the last 4 years, with Sep 2025 value amounting to $3.4 million.

  • Xeris Biopharma Holdings' Other Non-Current Liabilities fell 60.32% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 million, marking a year-over-year decrease of 60.32%. This contributed to the annual value of $2.0 million for FY2024, which is 59.43% down from last year.
  • According to the latest figures from Q3 2025, Xeris Biopharma Holdings' Other Non-Current Liabilities is $3.4 million, which was down 56.24% from $7.8 million recorded in Q2 2025.
  • Xeris Biopharma Holdings' Other Non-Current Liabilities' 5-year high stood at $30.2 million during Q2 2022, with a 5-year trough of $1.9 million in Q3 2021.
  • Over the past 3 years, Xeris Biopharma Holdings' median Other Non-Current Liabilities value was $6.1 million (recorded in 2024), while the average stood at $6.0 million.
  • Per our database at Business Quant, Xeris Biopharma Holdings' Other Non-Current Liabilities skyrocketed by 1,486.72% in 2022 and then plummeted by 83.06% in 2023.
  • Quarterly analysis of 5 years shows Xeris Biopharma Holdings' Other Non-Current Liabilities stood at $22.5 million in 2021, then rose by 14.01% to $25.7 million in 2022, then tumbled by 81.13% to $4.8 million in 2023, then crashed by 59.43% to $2.0 million in 2024, then crashed by 60.32% to $3.4 million in 2025.
  • Its last three reported values are $3.4 million in Q3 2025, $7.8 million for Q2 2025, and $4.8 million during Q1 2025.